Research Analysts Offer Predictions for ESPR Q4 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities research analysts at Zacks Research boosted their Q4 2026 EPS estimates for Esperion Therapeutics in a report released on Tuesday, March 31st. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn $0.04 per share for the quarter, up from their previous forecast of $0.03. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.10 EPS and FY2028 earnings at $0.39 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The company had revenue of $168.45 million during the quarter, compared to analysts’ expectations of $165.12 million.

A number of other brokerages have also issued reports on ESPR. Wall Street Zen upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Citizens Jmp raised their price objective on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the company a “market outperform” rating in a research report on Friday, March 13th. HC Wainwright reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Tuesday, March 10th. Needham & Company LLC boosted their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.60.

Esperion Therapeutics Trading Up 4.0%

Esperion Therapeutics stock opened at $2.74 on Wednesday. The stock has a 50 day moving average of $3.09 and a two-hundred day moving average of $3.17. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $4.18. The stock has a market capitalization of $702.38 million, a price-to-earnings ratio of -16.09, a PEG ratio of 1.89 and a beta of 1.11.

Institutional Trading of Esperion Therapeutics

A number of large investors have recently made changes to their positions in ESPR. Hsbc Holdings PLC purchased a new stake in shares of Esperion Therapeutics in the fourth quarter valued at $70,000. Caitong International Asset Management Co. Ltd lifted its position in Esperion Therapeutics by 17.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 36,744 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 5,492 shares during the period. Invesco Ltd. boosted its stake in Esperion Therapeutics by 23.5% in the 4th quarter. Invesco Ltd. now owns 765,118 shares of the biopharmaceutical company’s stock worth $2,831,000 after buying an additional 145,351 shares during the last quarter. Mackenzie Financial Corp grew its holdings in Esperion Therapeutics by 23.5% in the 4th quarter. Mackenzie Financial Corp now owns 336,992 shares of the biopharmaceutical company’s stock valued at $1,241,000 after buying an additional 64,034 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Esperion Therapeutics in the 4th quarter valued at about $599,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.